Navigation Links
Angiotech's novel 5-FU Central Venous Catheter receives FDA 510(k) clearance
Date:4/17/2008

ty at-large of creating a "super-bug" that is resistant to useful classes of antibiotics and antiseptics and may make infection control more complex. The alarming increase in microbial resistance is one of the Centers for Disease Control and Prevention's top concerns, and the 5-FU CVC represents an effective and important step towards preserving valuable antibiotic and antiseptic agents which currently have widespread use in the hospital and community settings.

The principle behind using 5-FU on a CVC is that the drug acts through multiple pathways to inhibit bacterial growth and metabolic functions of most microorganisms. Adding a very minute amount of 5-FU to the surface of a device makes that surface a hostile environment for a microorganism, with unchanged tolerability for the patient. This reduction in colonization by bacteria may have a net effect of reducing biofilm burden on the implanted devices, making them less likely to serve as reservoirs for additional infection.

Note on Forward Looking Statements

Statements contained in this press release that are not based on historical fact, including without limitation statements containing the words "believes," "may," "plans," "will," "estimate," "continue," "anticipates," "intends," "expects" and similar expressions, constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and constitute "forward-looking information" within the meaning of applicable Canadian securities laws. All such statements are made pursuant to the "safe harbor" provisions of applicable securities legislation. Forward-looking statements may involve, but are not limited to, comments with respect to our strategies or future actions, our targets, expectations for our financial condition and the results of, or outlook for, our operations, research development and product and drug development. Such forward-looking statements involve known and unknown risks, uncerta
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the Annual Meeting of the American Association for Cancer Research (AACR); Scientific Advisory Board Chairman Tyler Jacks Named President-elect
2. Kosan Presents Preclinical Data on Novel Third-Generation Hsp90 Inhibitors at AACR
3. Ardea Presents Preclinical Data on Novel Next Generation Non-Nucleoside Reverse Transcriptase Inhibitors Demonstrating Potent Anti-HIV Activity Against Resistant Viruses
4. Neptune Technologies patent granted for novel phospholipids in multiple diseases and pharmaceutical applications
5. Cephalon Receives FDA Approval for TREANDA, a Novel Chemotherapy for Chronic Lymphocytic Leukemia
6. Lentigen Corporation Announces Exclusive Licensing Agreement With Case Western Reserve University to Develop Novel Stem-Cell Therapy for Brain Cancer
7. 960-Patient Study Demonstrates Zero Blood Stream Infection In Patients Treated With Angiotechs Novel 5-FU Central Venous Catheter
8. Silence Therapeutics and AstraZeneca Announce Collaboration to Develop Novel Approaches for siRNA Drug Delivery
9. Vermillion and Stanford University Sign Exclusive License Agreement for Novel Biomarker Panel to Assess Peripheral Artery Disease Risk
10. ReachBio Partners with Axiogenesis to Distribute Novel Cell-Based Products in North America
11. Circassia Initiates Phase II Clinical Study With Novel Anti-Allergy Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... VIENNA , October 20, 2014 ... of gastrointestinal (GI) disorders and the delivery of care ... liver diseases and worrying inequalities in the provision of ... survey, which was commissioned by United European Gastroenterology (UEG), ... greater political and public awareness of the burden of ...
(Date:10/20/2014)... OncLive® is pleased to ... Thomas Jefferson University has joined its Strategic Alliance ... Partnership program, the Sidney Kimmel Cancer Center at ... of the Center’s cutting-edge research programs, comprehensive approach ... other health care professionals from the Sidney Kimmel ...
(Date:10/19/2014)... The Latin American hardware encryption display ... America with analysis and forecast of revenue. This market ... expected to reach $2,366.8 million by 2018, at a ... through the TOC of the Latin American hardware encryption ... analysis provided. It also provides a glimpse of the ...
(Date:10/19/2014)... 2014 The Asia-Pacific Bromine Market ... Asia-Pacific with analysis and forecast of revenue. , ... Bromine Market report, to get an idea of ... glimpse of the segmentation in the Asia-Pacific bromine ... figures. , http://www.micromarketmonitor.com/market/asia-pacific-bromine-6741503144.html , Bromine ...
Breaking Biology Technology:Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 2Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 3Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 4Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 5Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 2Sidney Kimmel Cancer Center at Thomas Jefferson University Partners With OncLive 3The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 2The Latin American hardware encryption display market is expected to reach $2,366.8 million by 2018 - New Report by MicroMarket Monitor 3The Asia-Pacific Bromine Market is estimated to grow to $4,080.1 million by 2018 - New Report by MicroMarket Monitor 2The Asia-Pacific Bromine Market is estimated to grow to $4,080.1 million by 2018 - New Report by MicroMarket Monitor 3
... Central Florida researcher may have found a defense against the ... Europe,s population in the Middle Ages and which government agencies ... Henry Daniell and his team have developed a vaccine that ... of his National Institutes of Health and USDA funded research ...
... They have worked for almost seven years in secret. ... in Ray Goehner,s materials characterization department at Sandia National ... of letters containing bacillus anthracis, the spores that cause ... fall of 2001 to several news media offices and ...
... consensus statement, the American College of Chest Physicians offers ... (WRA), a chronic respiratory condition that includes occupational asthma ... 25 percent of adults with asthma. Published as a ... the consensus statement, updated from 1995, places new emphasis ...
Cached Biology Technology:UCF professor develops vaccine to protect against black plague bioterror attack 2UCF professor develops vaccine to protect against black plague bioterror attack 3FBI unveils science of anthrax investigation 2FBI unveils science of anthrax investigation 3
(Date:10/15/2014)... resistance to bacterial pneumonia in female mice to an ... Females are naturally more resistant to respiratory infections than ... that increased resistance to bacterial pneumonia in female mice ... (NOS3). They also show that this enzyme is ultimately ... estrogen. , The team, lead by Professor Lester Kobzik ...
(Date:10/14/2014)... Research shows SIRT6—a protein known to inhibit the ... of skin cancers by turning on an enzyme that ... , Previously considered protective, SIRT6 is part of a ... genomic stability and prevent some of the genetic flaws ... can lead to cancer. This study, in the journal,s ...
(Date:10/14/2014)... 14, 2014 – High doses of fish oil supplements, rich ... common type of irregular heartbeat in which the heart can ... of the AFFORD trial led by the Montreal Heart Institute ... of Cardiology on October 7th. , For the trial, ... were randomly assigned to 4 grams of fish oil a ...
Breaking Biology News(10 mins):Two-faced gene: SIRT6 prevents some cancers but promotes sun-induced skin cancer 2
... UT Arlington bioengineer has received a four-year, $1.4 million ... system to shore up arterial walls following angioplasty and ... a UT Arlington associate professor of bioengineering, said the ... which opens arteries and blood vessels that are blocked., ...
... A team of researchers, led by physicians and ... Laboratories, has made a medical breakthrough by discovering genetic ... The disease, pulmonary capillary hemangiomatosis or PCH, is ... in young adults. PCH affects less than one in ...
... how the cells in our bodies divide could improve our knowledge ... Errors in the cell division process which allows us ... disorder called aneuploidy, which is also associated with birth defects and ... pinpointed the key role played by a protein in ensuring that ...
Cached Biology News:UT Arlington bioengineer to create new nanoparticle system to shore up arterial walls 2New hope: Researchers discover genetic mutations that cause rare and deadly lung disease 2New hope: Researchers discover genetic mutations that cause rare and deadly lung disease 3
MOUSE ANTI S. MUTANS PEPTIDOGLYCAN...
ANTI END CEL LUNG AG...
For the quantitative determination of canine Interleukin 10,(IL-10) concentrations in cell culture supernates, canine serum,and plasma....
EGTA, 50 g. Ethylene glycol-O,O-bis-[2-amino-ethyl]-N,N,N,N,-tetraacetic acid.Assay: > 99.0%. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
Biology Products: